Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Acute on Chronic Liver Failure SIG & Portal Hypertension SIG: Acute and Chronic Kidney Failure in Cirrhosis: Mechanisms to Management

    Contains 7 Component(s) Recorded On: 11/08/2019

    Acute on Chronic Liver Failure SIG & Portal Hypertension SIG: Acute and Chronic Kidney Failure in Cirrhosis: Mechanisms to Management presented at The Liver Meeting® 2019.

    This two-session program explores the pathophysiology, diagnosis and treatment of kidney failure in patients with cirrhosis. The first session reviews chronic kidney manifestations of portal hypertension, including sodium retention, ascites and chronic kidney failure. The second session discusses acute kidney injury in ACLF. Each part includes a case presentation to highlight management controversies, expert panel interviews and Q&A.

    Agustin Albillos
    Guadalupe Garcia-Tsao
    Constantine J. Karvellas
    Josh Levitsky
    Puneeta Tandon
    Florence Wong

  • Career Development Workshop

    Product not yet rated Contains 8 Component(s) Recorded On: 11/08/2019

    Career Development Workshop presented at The Liver Meeting® 2019.

    The Career Development Workshop is designed for hepatologists in the early career stage. Participants will explore how to maximize career opportunities in basic and clinical research, and will discuss potential sources of research funding for each pathway. They will also review an array of career pathways in both academic and community practice, and possible rewards and challenges hepatologists may encounter.

    Kimberly Ann Brown
    Oren K. Fix
    Ayman A. Koteish
    Valentina Medici
    Sonali Paul
    Elliot B. Tapper
    Monica A. Tincopa

  • Cholestatic and Autoimmune Liver Diseases SIG: Bile Acid Signaling and Cholestatic Liver Diseases

    Product not yet rated Contains 4 Component(s) Recorded On: 11/08/2019

    Cholestatic and Autoimmune Liver Diseases SIG: Bile Acid Signaling and Cholestatic Liver Diseases presented at The Liver Meeting® 2019.

    Recent approval of the synthetic FXR agonist obeticholic acid for primary biliary cholangitis treatment shows that targeting nuclear receptors in treating liver diseases, particularly cholestatic and autoimmune conditions, has therapeutic potential.

    Saul J. Karpen
    Keith D. Lindor
    Huiping Zhou

  • Clinical Practice SIG: Controversies in Clinical Hepatology

    Product not yet rated Contains 5 Component(s) Recorded On: 11/08/2019

    Clinical Practice SIG: Controversies in Clinical Hepatology presented at The Liver Meeting® 2019.

    What are the hotly debated issues in clinical hepatology today? At this session, explore current controversies in the field, including the role of statins, optimal management of acute gastric variceal bleeding and treatment of HCV in people who inject drugs. Speakers will then propose evidence-based guidance to address these difficult or challenging issues.

    Jaime Bosch
    Patrick Grant Northup
    Shiv Kumar Sarin
    Paul J. Thuluvath

  • Clinical Research Workshop: Microbiome as a Model of Clinical Research: From Stool to Study to Treatment

    Product not yet rated Contains 4 Component(s) Recorded On: 11/08/2019

    Clinical Research Workshop: Microbiome as a Model of Clinical Research: From Stool to Study to Treatment presented at The Liver Meeting® 2019.

    The microbiome is recognized as an important player in liver disease pathogenesis. The liver’s close proximity to the gut makes it particularly susceptible to changes in the intestinal microbiome. This workshop uses the microbiome as an example to facilitate appreciation of the tools available to perform clinical research, as well as specific research tactics for microbiome-related study.

    Mamatha Bhat
    Anna Mae Diehl
    Herbert Tilg

  • Hepatitis B SIG: Updates and Controversies in HBV: Management, HCC Surveillance and Emerging Therapies

    Product not yet rated Contains 4 Component(s) Recorded On: 11/08/2019

    Hepatitis B SIG: Updates and Controversies in HBV: Management, HCC Surveillance and Emerging Therapies presented at The Liver Meeting® 2019.

    This two-hour symposium explores chronic hepatitis B management in diverse populations. Topics include the changing global epidemiology and comorbidity of chronic hepatitis B, how to apply current practice guidelines in “gray” zones, HCC prevention strategies beyond the guidelines, emerging curative therapies and current strategies in HCC surveillance for hepatitis B, especially in younger, noncirrhotic persons from endemic areas.

    Henry Chan
    Harry Janssen
    Norah Terrault

  • Hepatitis C SIG: Improving the Care Continuum for Chronic HCV Infection in 2019

    Product not yet rated Contains 6 Component(s) Recorded On: 11/08/2019

    Hepatitis C SIG: Improving the Care Continuum for Chronic HCV Infection in 2019 presented at The Liver Meeting® 2019.

    Review steps to develop programs to eradicate HCV in the U.S. at this program. Speakers will address the current state of screening, novel models to engage more patients into therapy and the current state of access to HCV therapeutics, including generics. They will contrast U.S. efforts to eradicate HCV with programs from around the world.

    Sanjeev Arora
    Jonathan Fenkel
    Camilla Graham
    Lynn Taylor
    David Thomas

  • Hepatotoxicity SIG: Drug Induced Liver Injury: Assessing Risk and Predicting Outcome

    Contains 3 Component(s) Recorded On: 11/08/2019

    Hepatotoxicity SIG: Drug Induced Liver Injury: Drug Induced Liver Injury: Assessing Risk and Predicting Outcome presented at The Liver Meeting® 2019.

    Clinicians and translational researchers will glean approaches to assess drug induced liver injury (DILI) risk and predict outcomes at this session. Faculty will review basic hepatic drug metabolism in healthy and diseased livers, strategies to detect DILI during drug treatment and possible DILI risk factors, such as dose, duration, genetics and immunity. They will also share useful databases for clinicians.

    Jay H. Hoofnagle
    Craig Lammert

  • Liver Cell Biology in Hepatic Diseases SIG: Regenerative Medicine and the Bio-Artificial Liver

    Product not yet rated Contains 2 Component(s) Recorded On: 11/08/2019

    Liver Cell Biology in Hepatic Diseases SIG: Regenerative Medicine and the Bio-Artificial Liver presented at The Liver Meeting® 2019.

    Recent advances in liver bio-engineering have led to multiple in vitro culture systems that duplicate many complex cell-cell interactions of the intact liver. This symposium will highlight recent advances in this field, show current use of ex-vivo, 3D multicellular culture systems as probes of liver function and disease and update the progress toward the generation of the bio-artificial liver.

    George K. Michalopoulos

  • Liver Fibrosis SIG: Novel Approaches to Study and Treat Liver Fibrosis: From Bedside to Bench, and Bed Again?

    Contains 2 Component(s) Recorded On: 11/08/2019

    Liver Fibrosis SIG: Novel Approaches to Study and Treat Liver Fibrosis: From Bedside to Bench, and Bed Again? presented at The Liver Meeting® 2019.

    Experts review recent progress in liver fibrosis research at this session, focusing on new discoveries of the molecular mechanisms and translational aspects of fibrosis and cirrhosis, including translation of findings into humans; the potential role of non-parenchymal cells; new transcriptional and post-transcriptional regulation of key contributors of fibrosis; mechanisms that may lead to novel therapies; and an update on antifibrotics.

    Alan C. Mullen